Spyre Therapeutics, Inc. SYRE Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$69.01M-54.1% | -$62.53M-11.1% | -$11.18M+83.8% | -$36.72M+5.5% | -$44.77M-2.1% | ||
| $12.81M+44.6% | $9.81M+6.5% | $9.57M-27.0% | $9.38M+7.8% | $8.86M-36.0% | ||
| -$57.37M-40.0% | -$44.58M-19.8% | -$37.12M-26.2% | -$46.56M+25.2% | -$40.99M-43.6% | ||
| $56.58M+92,856% | -$247.41M-45.1% | $25M— | $79M+166% | -$61K+99.9% | ||
| $12.26M+9,704% | $312.81M+38.7% | -$4.64M-136% | $731K+103% | $125K-99.9% | ||
| $11.46M+128% | —— | -$16.76M— | —— | -$40.93M-206% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Spyre Therapeutics, Inc. generate?
- Spyre Therapeutics, Inc. (SYRE) generated -$185.6M in operating cash flow over the trailing twelve months.
- Where does Spyre Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Spyre Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.